Data presented shows that Hexvix® cystoscopy significantly improves time to recurrence of bladder cancer

Photocure to present data on impact of Hexvix®/Cysview® on long term recurrence rates at American Urological Association annual meeting, Atlanta, GA, USA. The results indicates that Hexvix cystoscopy significantly improves time to recurrence of bladder cancer.

Oslo, Norway, May 22 2012: Data will be presented on Photocures flagship product to aid in diagnosing bladder cancer, Hexvix/Cysview, at the American Urological Association (AUA) Annual Meeting in Atlanta, USA on Tuesday 22 May 2012.

The inside of a bladder with suspected bladder cancer. To the left you can see what it looks like with Hexvix in standard white light, and to the right with the blue light switched on.

The data on Hexvix/Cysview, from a long term follow-up study in 551 patients, indicates that Hexvix cystoscopy significantly improves time to recurrence of bladder cancer. Professor H. Barton Grossman, (Houston, TX) will be presenting this data on Tuesday 22 May at 11:00 am.

H. Barton Grossman, Clinical Professor, MD Anderson Cancer Center, commented: Hexvix/Cysview is a significant advance in detecting and treating bladder cancer. These data demonstrate that the recurrence of bladder cancer is reduced and importantly show a trend towards improved bladder preservation, which is of huge importance to patients and their quality of life.

Kjetil Hestdal, President and Chief Executive Officer of Photocure, commented: These positive long term follow-up data presented today at this prestigious conference are testament to the effectiveness of Hexvix in detecting bladder cancer. We are further encouraged by the positive response from urologists following the launch of Cysview in the US.

The data has been published in the online edition of the peer-reviewed Journal of Urology and can be found at the following link:

Hexvix/Cysview is the first approved drug-device combination procedure for improved detection of bladder cancer. It is designed to induce fluorescence in the malignant cells in the bladder during a cystoscopic procedure, making it easier for the urologist to detect non muscle invasive bladder cancer, as an adjunct to white light cystoscopy. It is the first product in a new diagnostic class known as Photodynamic Diagnostic (PDD) agents. Hexvix/Cysview is an approved product in Europe and the US.  Photocure markets and sells Hexvix in the Nordic region, and has initiated the commercialization of Cysview directly in the US. Ipsen is commercializing Hexvix in the rest of the world.

For further information, please contact:
President & CEO Kjetil Hestdal
Tel: + 47 913 19 535, Email:
Mary Clark, Amber Bielecka, Hollie Vile
Tel: +44 207920 2361, Email: